1. Home
  2. companies
  3. Xtandi

Xtandi

Medivation Poised To Expand As Xtandi Shows Efficacy In Advanced Triple Negative Breast Cancer
Medivation Poised To Expand As Xtandi Shows Efficacy In Advanced Triple Negative Breast Cancer
Seeking Alpha
Medivation
Xtandi
triple negative breast cancer
breast cancer
Should Johnson & Johnson Buy Medivation Inc.?
Should Johnson & Johnson Buy Medivation Inc.?
Motley Fool
JNJ
Medivation
M&A
Xtandi
prostate cancer
Sovaldi's not the only superhero launch: Meet the rest of the pharma Avengers
Sovaldi's not the only superhero launch: Meet the rest of the pharma Avengers
Fierce Pharma Marketing
Sovaldi
Gilead Sciences
Eyelea
Tecfidera
Zytiga
Kalydeco
Vertex Pharmaceuticals
Victoza
Novo Nordisk
Gilenya
Yervoy
Xtandi
Stribild
Stelara
Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline
Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline
TheStreet.com
prostate cancer
Medivation
Xtandi
J&J Likely To Report Drop In Zytiga Sales On Xtandi‘s Entry In Prostate Cancer Market
J&J Likely To Report Drop In Zytiga Sales On Xtandi‘s Entry In Prostate Cancer Market
Bidness Etc.
Zytiga
Xtandi
JNJ
prostate cancer
Medivation
Astellas
Xtandi field force to increase by 50% for market-share battle with Zytiga
Xtandi field force to increase by 50% for market-share battle with Zytiga
Fierce Pharma Marketing
Xtandi
Medivation
Astellas
hirings
JNJ
Zytiga
U.S. FDA okays expanded use of Medivation prostate cancer drug
U.S. FDA okays expanded use of Medivation prostate cancer drug
Yahoo/Reuters
Medivation
FDA
prostate cancer
Xtandi
Is This Johnson & Johnson's Worst Nightmare?
Is This Johnson & Johnson's Worst Nightmare?
Motley Fool
JNJ
Zytiga
Medivation
Xtandi
Olysio
Gilead Sciences
Sovaldi
New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial Of Enzalutamide In Men With Chemotherapy-Naïve Metastatic Prostate Cancer
New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial Of Enzalutamide In Men With Chemotherapy-Naïve Metastatic Prostate Cancer
Yahoo/BusinessWire
Enzalutamide
prostate cancer
metastatic prostate cancer
Xtandi
Astellas
Companies Betting on the Next 10 Blockbuster Drugs
Companies Betting on the Next 10 Blockbuster Drugs
24/7WallStreet
Juxtapid
Otezla
Aegerion
Celgene
GW Pharma
Sativex
Intercept Pharma
OCA
Ironwood Pharmaceuticals
Linzess
Lpath
iSONEP
MannKind
Afrezza
Xtandi
H.P. Acthar Gel
Questcor Pharmaceuticals
eteplirsen
Sarepta Therapeutics
Biotech Stock Roundup: Strong Show from Biogen & Alexion; Medivation PREVAILs
Biotech Stock Roundup: Strong Show from Biogen & Alexion; Medivation PREVAILs
Yahoo/Zacks.com
Biogen Idec
Alexion
Medivation
Xtandi
This Week in Biotech: Let's Get Clinical!
This Week in Biotech: Let's Get Clinical!
Motley Fool
AbbVie
Enanta Pharmaceuticals
ABT-450
hepatitis C
Medivation
Xtandi
prostate cancer
Astellas
Geron
imetelstat
PSMA-ADC
Progenics Pharmaceuticals
Idenix
Medivation Inc. and Astellas Up the Ante against Johnson & Johnson
Medivation Inc. and Astellas Up the Ante against Johnson & Johnson
Motley Fool
Medivation
Astellas
JNJ
Zytiga
Xtandi
prostate cancer
Medivation prostate cancer drug impresses in pre-chemo study
Medivation prostate cancer drug impresses in pre-chemo study
Yahoo/Reuters
Medivation
prostate cancer
Xtandi
Slowing Sales for Johnson & Johnson's Zytiga May Be Good News for Medivation
Slowing Sales for Johnson & Johnson's Zytiga May Be Good News for Medivation
Motley Fool
JNJ
Zytiga
Medivation
Xtandi
prostate cancer
Johnson & Johnson And Medivation: A Prostate Cancer Marketshare
Johnson & Johnson And Medivation: A Prostate Cancer Marketshare
Seeking Alpha
JNJ
Medivation
prostatce cancer
Astellas
Dendreon
Sanofi
Zytiga
Xtandi
Provenge
Johnson & Johnson Vs. Medivation In Prostate Cancer Race
Johnson & Johnson Vs. Medivation In Prostate Cancer Race
Seeking Alpha
JNJ
Medivation
prostate cancer
Xtandi
Astellas
Zytiga
Here's Why Medivation Jumped Higher This Week
Here's Why Medivation Jumped Higher This Week
Motley Fool
Medivation
Xtandi
prostate cancer
Can Xtandi Become the Go-To Prostate Drug?
Can Xtandi Become the Go-To Prostate Drug?
Motley Fool
Xtandi
prostate cancer
Medivation
Astellas
Dendreon: Crushed By JNJ/Medivation Or By Own Management?
Dendreon: Crushed By JNJ/Medivation Or By Own Management?
Seeking Alpha
JNJ
Medivation
Dendreon
Provenge
Xtandi
Zytiga
prostate cancer

Click here to subscribe to daily news headlines in your email inbox